SAMHSA Applauds Expansion of Access to Medication for Opioid Use Disorder (MOUD)

SAMHSA Applauds Expansion of Access to Medication for Opioid Use Disorder (MOUD)

The Substance Abuse and Mental Health Services Administration (SAMHSA) applauds provisions included in the 2023 Consolidated Appropriations Act (P.L. 117-328) that will significantly expand access to medication for opioid use disorder (MOUD). The act, signed into law by President Biden on Dec. 29, 2022, amended the Controlled Substances Act to eliminate the requirement for qualified…

A Horrifying Drug Called ‘Tranq Dope’ Is Spreading in the US

A Horrifying Drug Called ‘Tranq Dope’ Is Spreading in the US

The animal tranquilizer xylazine, which has been linked to severe wounds and amputations, has been detected in nearly 40 states. VICE | Manisha Krishnan November 15, 2022 After two years of sobriety, Allie Gramlich began using drugs again in April. This time around, Philadelphia’s street opioid supply was infiltrated with tranq or tranq dope, a…

A major drugmaker plans to sell overdose-reversal nasal spray Narcan over the counter
|

A major drugmaker plans to sell overdose-reversal nasal spray Narcan over the counter

Brain Mann | NPR Dec. 13, 2022 Drug maker Emergent BioSolutions is seeking approval from the Food and Drug Administration to sell Narcan over the counter, without need for a prescription. The medication, an easy-to-use nasal spray version of the drug naloxone, has a strong track record reversing deadly opioid overdoses, which have soared in…

Fentanyl Vaccine Potential ‘Game Changer’ for Opioid Epidemic 

Fentanyl Vaccine Potential ‘Game Changer’ for Opioid Epidemic 

Study Suggests New Vaccine Could Prevent Deadly Opioid from Entering the Brain By Laurie Fickman 713-743-8454 November 14, 2022 A research team led by the University of Houston has developed a vaccine targeting the dangerous synthetic opioid fentanyl that could block its ability to enter the brain, thus eliminating the drug’s “high.” The breakthrough discovery could have…

CVS, Walmart, Walgreens agree to pay $13.8 bln to settle U.S. opioid claims
| |

CVS, Walmart, Walgreens agree to pay $13.8 bln to settle U.S. opioid claims

Nov 2 (Reuters) – CVS Health Corp, Walgreens Boots Alliance Inc and Walmart Inc agreed to pay about $13.8 billion to resolve thousands of U.S. state and local lawsuits accusing the pharmacy chains of mishandling opioid pain drugs, potentially bringing years of litigation close to the finish line. CVS said on Wednesday it had agreed…